Bristol Myesrs Squibb & Exscientia In $1.2 billion Artificial Intelligence Drug Discovery Deal

Bristol Myers Squibb (BMS) has announced a new collaboration agreement with Exscientia to use artificial intelligence (AI) to discovery drug candidates across a number of therapeutic areas. The collaboration will leverage Exscientia‚Äôs AI technology to accelerate the discovery of small molecule therapeutic drug candidates in multiple therapeutic areas, including oncology and immunology. As part of…

Alkem Laboratories Research Report by Angel Broking

Slower growth in domestic and US business: Alkem reported yoy revenue grew of 9% in 4QFY17. Domestic revenue grew by 7% yoy to `856cr while exports grew by 14.5% to `385cr. US revenue grew by 19.4% yoy to `291cr. Other exports were flat at `95cr. Domestic business contributed 69% of the total revenue during the…